As the developed markets are becoming increasingly mature, Pharma is turning to the emerging markets, where long-term growth can be sustained. Of particular interest are Indonesia and the Philippines, which are currently going through major reforms to expand their healthcare systems; however there are key differences between these two markets.
Scope
* Provides a comparative overview of recent events affecting the macroeconomic and pharmaceutical landscape
* Examines different drivers and resistors for growth in Indonesia and the Philippines
* Analyzes the growth drivers of multinational and domestic players operating in these markets
* Identifies key strategies for entry and expansion in these markets
Highlights
The global economic downturn has impacted Indonesia, albeit at a lesser extent than developed countries. Indonesia's economic prowess has resulted in the country potentially joining the top tier of emerging markets including Brazil, Russia, India and China in the near future, as these are to grow at a faster rate than developed countries.
With the introduction of a single South East Asian market via the free trade agreement Association of South East Asian Nations (ASEAN) from 2011, in addition to a full universal insurance coverage in the Philippines and Indonesia by 2010 and 2013, respectively, the opportunity of pharmaceutical players to maximize sales will increase.
Domestic pharmaceutical companies in both Indonesia and the Philippines are ideal M&A targets for multinationals looking to enter or expand in these markets. This is due to their double digit sales growth, which will be further fuelled by the growing demand for low cost medicine as healthcare coverage expands.
Partial Table of Contents:
-- Full ToC is available at http://www.fastmr.com/
ABOUT DATAMONITOR HEALTHCARE
About the Strategic Pharmaceutical Analysis Team
1. Executive Summary
Strategic scoping and focus
Key Findings
Socioeconomic comparison - Indonesia has a larger patient potential but the Philippines is more attractive in the short-term due to greater healthcare access
Pharmaceutical market comparison - the larger market size, growth rate and brand preference makes the Philippines an attractive market for multinationals
Regulatory comparison - both Indonesia and the Philippines have difficult regulatory environments
Related reports
Table of Contents
2. The pharmaceutical market in Indonesia
Despite a large patient potential, the requirement for a domestic manufacturing hub impacts the many foreign players
Demographic trends in Indonesia
Summary of socioeconomic environment in Indonesia
Political environment - the Democratic party fostered stability and economic growth
Gross domestic product (GDP) growth has been increasing but from 2009 it will be affected negatively by the financial turmoil
The healthcare system in Indonesia
Healthcare expenditure in Indonesia is low, but set to increase
Health insurance does not cover the whole population despite the availability of several different schemes
Universal health insurance aims to improve health outcomes and cover all Indonesians by 2013
Funding healthcare reforms
Indonesia's transition to universal healthcare coverage
Regulatory issues in Indonesia
Protection of intellectual property rights are weak and counterfeit drugs are a major problem
Registration of drugs aims to protect the local industry
Pricing and Reimbursement in Indonesia
Continuous price cuts incentivize generics and pose a threat to multinational branded pharma companies
Drug labeling now required to include price and generic name
Rising costs of raw materials has resulted in escalating drug prices
Reimbursement is very limited
Pharmaceutical market dynamics
Branded generics dominate the Indonesian market
Top pharmaceutical companies in Indonesia
Top international pharmaceutical companies
Bayer
Novartis
Pfizer
Analysis of top domestic pharmaceutical companies
Kalbe Farma
Sanbe
Dexa Medica
Soho
Pharos
Kimia Farma and Indofarma
Top therapeutic areas by sales value
Top pharmaceutical brands
3. The pharmaceutical market in the Philippines
Government-imposed price cuts and measures to boost generics are creating a more challenging environment for Big Pharma
Demographic trends in the Philippines
Summary of socioeconomic environment in the Philippines
For more information or to purchase this report, go to http://www.fastmr.com/
About Datamonitor
The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment. View more research from Datamonitor at http://www.fastmr.com/
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
